ENDRA Life Sciences Total Assets 2011-2026 | NDRA

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets ENDRA Life Sciences

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
3.85 M	4.45 M	6.75 M	9.27 M	12.9 M	8.76 M	7.18 M	7.22 M	6.12 M	491 K	487 K	703 K	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
12.9 M	487 K	5.68 M

Quarterly Total Assets ENDRA Life Sciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
1.96 M	2.81 M	3.17 M	4.45 M	-	10.4 M	5.06 M	6.75 M	7.6 M	9.24 M	6.65 M	9.27 M	12.3 M	15.3 M	10.9 M	12.9 M	15.3 M	17.2 M	18.9 M	8.76 M	5.36 M	8.76 M	8.76 M	7.18 M	7.18 M	7.18 M	7.18 M	7.22 M	7.22 M	7.22 M	7.22 M	6.12 M	6.12 M	6.12 M	6.12 M	491 K	491 K	491 K	491 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
18.9 M	491 K	7.53 M

Total Assets of other stocks in the Diagnostics research industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	77.2 M	-	-6.23 %	$ 30.6 M	Germany
Burning Rock Biotech Limited BNR	2.28 B	$ 15.85	-2.49 %	$ 171 M	China
Agilent Technologies A	10.7 B	$ 115.06	-0.29 %	$ 35 B	USA
Aspira Women's Health AWH	5.46 M	-	-6.19 %	$ 10.5 M	USA
Biocept BIOC	30.9 M	-	-13.05 %	$ 7.29 M	USA
BioNano Genomics BNGO	73.6 M	$ 1.13	-2.59 %	$ 6.15 M	USA
Chembio Diagnostics CEMI	62.6 M	-	0.22 %	$ 16.8 M	USA
Check-Cap Ltd. CHEK	377 K	-	-	$ 9.42 M	Israel
DermTech DMTK	122 M	-	-11.32 %	$ 2.94 M	USA
CareDx, Inc CDNA	413 M	$ 16.05	-3.83 %	$ 855 M	USA
Oxford Immunotec Global PLC OXFD	235 M	-	-	$ 562 M	Britain
Akumin AKU	1.77 B	-	-17.87 %	$ 25.9 M	Canada
Enzo Biochem ENZ	85.8 M	-	-8.98 %	$ 14.8 K	USA
Co-Diagnostics CODX	24.7 M	$ 4.4	101.83 %	$ 5.85 M	USA
Exact Sciences Corporation EXAS	5.86 B	-	-	$ 19.8 B	USA
Accelerate Diagnostics AXDX	65 M	-	-61.36 %	$ 2.46 M	USA
Castle Biosciences CSTL	531 M	$ 23.13	-1.28 %	$ 642 M	USA
Global Cord Blood Corporation CO	8.53 B	-	-	$ 399 M	China
Fluidigm Corporation FLDM	325 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	20.8 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	975 M	-	0.12 %	$ 80.1 M	China
Interpace Biosciences IDXG	33.8 M	$ 2.3	-	$ 10.2 M	USA
Charles River Laboratories International CRL	7.14 B	$ 175.65	0.06 %	$ 8.71 B	USA
PRA Health Sciences, Inc. PRAH	4.18 B	-	-	$ 10.7 B	USA
Danaher Corporation DHR	83.5 B	$ 189.61	-1.7 %	$ 135 B	USA
Heska Corporation HSKA	586 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	17.8 M	-	-20.0 %	$ 1.06 M	USA
Medpace Holdings MEDP	1.98 B	$ 493.53	-1.59 %	$ 14.2 B	USA
Illumina ILMN	6.3 B	$ 120.93	-2.22 %	$ 19.2 B	USA
Fulgent Genetics FLGT	1.22 B	$ 14.43	-3.93 %	$ 436 M	USA
Myriad Genetics MYGN	707 M	$ 4.35	-2.03 %	$ 403 M	USA
NeoGenomics NEO	1.36 B	$ 7.69	-3.17 %	$ 985 M	USA
Guardant Health GH	2.01 B	$ 78.6	-9.83 %	$ 9.85 B	USA
QIAGEN N.V. QGEN	6.28 B	-	-	$ 10.6 B	Niderland
Anixa Biosciences ANIX	16.1 M	$ 2.69	-1.82 %	$ 87.3 K	USA
Biomerica BMRA	5.94 M	$ 2.13	-0.9 %	$ 4.89 M	USA
Invitae Corporation NVTA	1.95 B	-	-	$ 21.2 M	USA
Koninklijke Philips N.V. PHG	26.9 B	$ 28.31	0.62 %	$ 20 B	Niderland
ICON Public Limited Company ICLR	16.9 B	$ 106.81	0.1 %	$ 8.81 B	Irlanda
Laboratory Corporation of America Holdings LH	18.4 B	$ 260.93	-4.51 %	$ 21.7 B	USA
Natera NTRA	1.39 B	$ 193.03	-4.91 %	$ 19 B	USA
Celcuity CELC	467 M	$ 117.14	-6.02 %	$ 5.48 B	USA
Lantheus Holdings LNTH	2.23 B	$ 80.59	-1.03 %	$ 5.44 B	USA
Motus GI Holdings MOTS	7.22 M	-	-34.28 %	$ 263 K	Israel
Quest Diagnostics Incorporated DGX	16.2 B	$ 191.51	-3.19 %	$ 21.3 B	USA
Neogen Corporation NEOG	3.44 B	$ 9.42	-6.13 %	$ 2.04 B	USA
Organovo Holdings ONVO	14.6 M	-	-2.3 %	$ 19.4 M	USA
OpGen OPGN	9.86 M	-	-16.95 %	$ 1.54 M	USA
National Research Corporation NRC	135 M	$ 16.48	-3.34 %	$ 369 M	USA